ArticleGlomerular diseases
Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: An Immunologic Crossroads.
Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is largely regarded as a form of monoclonal gammopathy of renal significance; however, 70-80% of cases lack evidence of an associated monoclonal lymphoproliferative disorder. Emerging evidence suggests it is a shared clinicopathologic manifestation of multiple, distinct disease etiologies including infection, autoimmunity, complement dysregulation, and neoplasia. Development of a more precise, etiology-based system of classification is hindered by limitations in adequately characterizing the clonal nature of monotypic deposits in renal tissue. Furthermore, the current body of evidence evaluating effective treatment options for PGNMID is limited by retrospective data, small sample sizes, and variability in treatment regimens. As a result, treatment strategies are largely extrapolated from established therapies used in overt hematologic malignancies. Summary: In this review, we discuss the classification, pathogenesis, clinicopathologic features, diagnostic challenges, and treatment approach for PGNMID. Key Message: The heterogenous nature and lack of consensus to guide the management of PGNMID highlights the need for an individualized and multidisciplinary team approach involving nephrologists, hematologists, and nephropathologists. Practicing clinicians need to be aware of the limitations of diagnostic tools used in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.